PSME2

Proteasome activator complex subunit 2 · Q9UL46 · PSME2 on Sugi Atlas →

0 patent compounds predicted against PSME2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PSME2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma PHASE2WITHDRAWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer PHASE2COMPLETED
A Prevention Trial in Subjects at High Risk for Breast Cancer PHASE2COMPLETED
Bortezomib in Treating Patients With Mantle Cell Lymphoma PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma PHASE2WITHDRAWN
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Studying TAK-243 in Patients With Advanced Cancer PHASE1RECRUITING
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma PHASE1COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas PHASE1COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSME2 binder may also engage these)

ProteinNameSimilarity
Q5E9G3 1.000 Q5E9G3 →
Q863Z0 1.000 Q863Z0 →
P97372 1.000 P97372 →
Q63798 1.000 Q63798 →
P58238 1.000 P58238 →
P97371 1.000 P97371 →
Q64L94 1.000 Q64L94 →
Q4U5R3 1.000 Q4U5R3 →
Q967U1 1.000 Q967U1 →
PSME1 Proteasome activator complex subunit 1 0.999 landscape →
Q63797 0.995 Q63797 →
P45966 0.995 P45966 →
Q9U2Y2 0.994 Q9U2Y2 →
Q9W1F4 0.993 Q9W1F4 →
P47805 0.993 P47805 →
Q6NLQ3 0.993 Q6NLQ3 →
Q9HDW4 0.992 Q9HDW4 →
Q9N3Q8 0.992 Q9N3Q8 →
Q5XG71 0.992 Q5XG71 →
A1ZB91 0.992 A1ZB91 →
Q750S2 0.992 Q750S2 →
Q60V43 0.992 Q60V43 →
B4GH42 0.992 B4GH42 →
Q17QK1 0.992 Q17QK1 →
O94376 0.991 O94376 →
Q23H79 0.991 Q23H79 →
B3DL65 0.991 B3DL65 →
O14017 0.991 O14017 →
Q5XG48 0.991 Q5XG48 →
Q8STE5 0.991 Q8STE5 →